Nanosonics (NAN) Stock Overview
Operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NAN Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nanosonics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.40 |
| 52 Week High | AU$5.08 |
| 52 Week Low | AU$3.21 |
| Beta | 1.21 |
| 1 Month Change | -7.61% |
| 3 Month Change | -11.23% |
| 1 Year Change | -30.04% |
| 3 Year Change | -39.29% |
| 5 Year Change | -33.98% |
| Change since IPO | 314.63% |
Recent News & Updates
Narrative Update • May 07
NAN: Premier Agreement And Stable Outlook Will Support Future Upside Potential
Analysts have modestly revised their view on Nanosonics, updating its A$ fair value to reflect slightly different assumptions around discount rate, revenue growth, profit margin and future P/E, which in turn leads to a small change in the overall price target rationale. What's in the News Nanosonics Inc.
Narrative Update • Apr 22
NAN: Premier Agreement Will Support Future Upside Potential
Analysts have kept their fair value estimate for Nanosonics broadly unchanged at A$4.30, making small adjustments to the discount rate, profit margin assumptions and future P/E input. These changes have led to only a marginal shift in the implied price target rather than a major reset in expectations.Narrative Update • Apr 06
NAN: RBC Upgrade And Premier Agreement Will Support Future Upside Potential
Analysts have modestly adjusted their assumptions for the discount rate, revenue growth, profit margin and future P/E in their models for Nanosonics. They have kept the fair value estimate steady at A$4.30 and anchored their view to recent research upgrades on the stock.Narrative Update • Mar 22
NAN: RBC Upgrade And Higher Future P/E Will Support Upside Potential
Narrative Update on Nanosonics The analyst price target for Nanosonics has been adjusted slightly higher from A$5.43 to about A$5.43, as analysts factor in updated assumptions for discount rate, revenue growth, profit margin, and a higher future P/E multiple, supported by recent positive Street research, including the RBC Capital upgrade. Analyst Commentary Bullish analysts have taken a more constructive view on Nanosonics, reflected in updated assumptions for discount rate, revenue growth, profit margin, and a higher future P/E multiple.Narrative Update • Mar 08
NAN: RBC Upgrade And Premier Agreement Will Support Long Term Upside
Analysts have trimmed their price target on Nanosonics from about A$4.75 to around A$4.30, reflecting updates to their models that now assume a slightly higher discount rate, more moderate revenue growth, a somewhat higher profit margin, and a lower future P/E multiple, consistent with recent research commentary, including the upgrade from RBC Capital. Analyst Commentary Recent Street research, including the upgrade from RBC Capital, highlights where analysts see both opportunity and risk for Nanosonics at the current valuation.Recent updates
Narrative Update • May 07
NAN: Premier Agreement And Stable Outlook Will Support Future Upside Potential
Analysts have modestly revised their view on Nanosonics, updating its A$ fair value to reflect slightly different assumptions around discount rate, revenue growth, profit margin and future P/E, which in turn leads to a small change in the overall price target rationale. What's in the News Nanosonics Inc.Narrative Update • Apr 22
NAN: Premier Agreement Will Support Future Upside Potential
Analysts have kept their fair value estimate for Nanosonics broadly unchanged at A$4.30, making small adjustments to the discount rate, profit margin assumptions and future P/E input. These changes have led to only a marginal shift in the implied price target rather than a major reset in expectations.Narrative Update • Apr 06
NAN: RBC Upgrade And Premier Agreement Will Support Future Upside Potential
Analysts have modestly adjusted their assumptions for the discount rate, revenue growth, profit margin and future P/E in their models for Nanosonics. They have kept the fair value estimate steady at A$4.30 and anchored their view to recent research upgrades on the stock.Narrative Update • Mar 22
NAN: RBC Upgrade And Higher Future P/E Will Support Upside Potential
Narrative Update on Nanosonics The analyst price target for Nanosonics has been adjusted slightly higher from A$5.43 to about A$5.43, as analysts factor in updated assumptions for discount rate, revenue growth, profit margin, and a higher future P/E multiple, supported by recent positive Street research, including the RBC Capital upgrade. Analyst Commentary Bullish analysts have taken a more constructive view on Nanosonics, reflected in updated assumptions for discount rate, revenue growth, profit margin, and a higher future P/E multiple.Narrative Update • Mar 08
NAN: RBC Upgrade And Premier Agreement Will Support Long Term Upside
Analysts have trimmed their price target on Nanosonics from about A$4.75 to around A$4.30, reflecting updates to their models that now assume a slightly higher discount rate, more moderate revenue growth, a somewhat higher profit margin, and a lower future P/E multiple, consistent with recent research commentary, including the upgrade from RBC Capital. Analyst Commentary Recent Street research, including the upgrade from RBC Capital, highlights where analysts see both opportunity and risk for Nanosonics at the current valuation.Narrative Update • Feb 21
NAN: RBC Upgrade And Refreshed Assumptions Will Support Future Upside Potential
Analysts have maintained Nanosonics' fair value estimate at A$5.43. The latest price target update is supported by refreshed assumptions for the discount rate, revenue growth, profit margin, and future P/E, following recent research that includes an upgrade highlighted by RBC Capital.Narrative Update • Feb 07
NAN: RBC Upgrade And Refined Assumptions Will Support Upside Potential
Analysts have modestly adjusted their price targets on Nanosonics to A$5.43, reflecting small tweaks to their assumptions on discount rate, revenue growth, profit margins and future P/E, supported by recent research that cites a more constructive stance on the stock. Analyst Commentary Recent research points to a more constructive tone around Nanosonics, with bullish analysts highlighting that the refreshed price targets around A$5.43 are consistent with their updated view on risk, earnings quality and execution.
Narrative Update • Jan 24
NAN: Share Buyback And Execution Risks Will Shape Future Performance
Analysts have maintained their price target on Nanosonics at A$4.00, reflecting slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E following recent research updates, including the upgrade at RBC Capital. Analyst Commentary While the latest research includes an upgrade, bearish analysts still highlight several risks that they see as constraints on upside and drivers of more cautious price targets.Narrative Update • Jan 10
NAN: Share Buyback Will Signal Confidence While Fair Value Suggests Upside
Analysts have adjusted their price target for Nanosonics to A$5.43, reflecting updated assumptions around revenue, profit margins and future P/E that they see as better aligned with the company’s current risk profile and earnings outlook. What's in the News Nanosonics Limited (ASX:NAN) has announced a share repurchase program of up to A$20 million, with the program valid until November 4, 2026 (Key Developments).Narrative Update • Dec 26
NAN: Share Buyback And Modest Margin Outlook Will Shape Future Performance
Analysts have nudged their price target on Nanosonics slightly higher to reflect modestly improved assumptions for revenue growth, profit margins and fair value, partly offset by a marginally higher discount rate and a slightly lower future P/E multiple. What's in the News Nanosonics Limited (ASX:NAN) has announced a share repurchase program of up to $20 million, valid until November 4, 2026 (company announcement) The Board of Directors has formally authorized the new share buyback plan as of November 5, 2025 (company announcement) Valuation Changes Fair Value has risen slightly, with the analyst estimate moving from 3.9 to 4.0 times long term earnings assumptions.Narrative Update • Dec 12
NAN: Share Buyback Will Signal Confidence Despite Higher Required Returns
Analysts have trimmed their price target for Nanosonics from A$6.18 to A$5.43. This reflects a higher required discount rate and lower expected valuation multiples, even as they modestly upgrade assumptions for revenue growth and profit margins.Analysis Article • Nov 05
With EPS Growth And More, Nanosonics (ASX:NAN) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Oct 07
With Nanosonics Limited (ASX:NAN) It Looks Like You'll Get What You Pay For
Nanosonics Limited's ( ASX:NAN ) price-to-earnings (or "P/E") ratio of 66.9x might make it look like a strong sell...Analysis Article • Jul 04
Nanosonics Limited's (ASX:NAN) Intrinsic Value Is Potentially 31% Above Its Share Price
Key Insights Nanosonics' estimated fair value is AU$5.03 based on 2 Stage Free Cash Flow to Equity Nanosonics is...Analysis Article • Mar 30
Nanosonics (ASX:NAN) Ticks All The Boxes When It Comes To Earnings Growth
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Feb 26
We Think Nanosonics' (ASX:NAN) Solid Earnings Are Understated
Nanosonics Limited ( ASX:NAN ) announced a healthy earnings result recently, and the market rewarded it with a strong...Analysis Article • Feb 24
Nanosonics Limited's (ASX:NAN) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, Nanosonics Limited ( ASX:NAN ) shares have been powering on, with a gain of 26% in the...
New Narrative • Feb 10
CORIS FDA Filing Will Set New Standard In Endoscopy Reprocessing
Strategic growth in high-margin recurring revenue and further North American market penetration in the trophon business suggest enhanced revenue and net margins.Analysis Article • Jan 22
Nanosonics Limited (ASX:NAN) Shares Could Be 24% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Nanosonics fair value estimate is AU$4.92 Nanosonics' AU$3.75...Analysis Article • Nov 28
Nanosonics (ASX:NAN) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Sep 18
Nanosonics Limited's (ASX:NAN) Shares Climb 29% But Its Business Is Yet to Catch Up
Nanosonics Limited ( ASX:NAN ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Analysis Article • Feb 27
Returns On Capital At Nanosonics (ASX:NAN) Paint A Concerning Picture
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Jan 24
Some Confidence Is Lacking In Nanosonics Limited (ASX:NAN) As Shares Slide 33%
Nanosonics Limited ( ASX:NAN ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Nov 08
Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?
Nanosonics Limited ( ASX:NAN ), is not the largest company out there, but it saw a double-digit share price rise of...Analysis Article • Oct 04
Investors Will Want Nanosonics' (ASX:NAN) Growth In ROCE To Persist
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Analysis Article • Jul 12
Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?
While Nanosonics Limited ( ASX:NAN ) might not be the most widely known stock at the moment, it saw significant share...Analysis Article • May 16
Nanosonics (ASX:NAN) Will Be Hoping To Turn Its Returns On Capital Around
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Feb 09
Is Now The Time To Look At Buying Nanosonics Limited (ASX:NAN)?
Nanosonics Limited ( ASX:NAN ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Analysis Article • Nov 11
This Is Why Nanosonics Limited's (ASX:NAN) CEO Compensation Looks Appropriate
Performance at Nanosonics Limited ( ASX:NAN ) has been rather uninspiring recently and shareholders may be wondering...Analysis Article • Oct 28
A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nanosonics Limited...Analysis Article • Oct 06
What Does Nanosonics Limited's (ASX:NAN) Share Price Indicate?
Nanosonics Limited ( ASX:NAN ), is not the largest company out there, but it saw a decent share price growth in the...Analysis Article • Jul 18
A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)
Today we will run through one way of estimating the intrinsic value of Nanosonics Limited ( ASX:NAN ) by estimating the...Analysis Article • Jun 26
At AU$3.36, Is Nanosonics Limited (ASX:NAN) Worth Looking At Closely?
Nanosonics Limited ( ASX:NAN ), is not the largest company out there, but it saw a double-digit share price rise of...Analysis Article • Jun 07
Nanosonics (ASX:NAN) Will Want To Turn Around Its Return Trends
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Analysis Article • Mar 08
A Look At The Intrinsic Value Of Nanosonics Limited (ASX:NAN)
How far off is Nanosonics Limited ( ASX:NAN ) from its intrinsic value? Using the most recent financial data, we'll...Shareholder Returns
| NAN | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 1.2% | -0.2% | 0.2% |
| 1Y | -30.0% | -47.1% | 5.8% |
Return vs Industry: NAN exceeded the Australian Medical Equipment industry which returned -47.1% over the past year.
Return vs Market: NAN underperformed the Australian Market which returned 5.8% over the past year.
Price Volatility
| NAN volatility | |
|---|---|
| NAN Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 10.7% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.5% |
Stable Share Price: NAN has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NAN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 470 | Michael Kavanagh | www.nanosonics.com.au |
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform.
Nanosonics Limited Fundamentals Summary
| NAN fundamental statistics | |
|---|---|
| Market cap | AU$1.02b |
| Earnings (TTM) | AU$20.56m |
| Revenue (TTM) | AU$207.26m |
49.5x
P/E Ratio4.9x
P/S RatioIs NAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAN income statement (TTM) | |
|---|---|
| Revenue | AU$207.26m |
| Cost of Revenue | AU$47.34m |
| Gross Profit | AU$159.92m |
| Other Expenses | AU$139.36m |
| Earnings | AU$20.56m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.069 |
| Gross Margin | 77.16% |
| Net Profit Margin | 9.92% |
| Debt/Equity Ratio | 0% |
How did NAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/09 20:46 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanosonics Limited is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Josh Kannourakis | Barrenjoey Markets Pty Limited |
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |